HIND Vyome Holdings, Inc

Nasdaq Pharmaceutical Preparations DE CIK: 0001427570
AI RATING
STRONG_SELL
88% Confidence

Investment Thesis

Vyome Holdings exhibits an unsustainable business model with $10.3M annual net losses against only $319.7K in revenue, requiring 30+ years of current growth just to break even. Despite healthy 68.4% gross margins and 24.4% revenue growth, the company is burning $3.7M in operating cash annually with only $5M cash reserves, providing approximately 1.4 years of runway. The massive operating expense base relative to revenue scale indicates fundamental business model challenges requiring significant operational restructuring.

Strengths

  • + Strong gross margin of 68.4% demonstrates viable product economics and pricing power
  • + Positive revenue growth of 24.4% YoY indicates market demand for offerings
  • + Adequate short-term liquidity with current ratio of 1.99x and $5M cash reserve

Risks

  • ! Catastrophic operating losses of $10.3M against $319.7K revenue represents structurally unsustainable economics
  • ! Negative operating cash flow of $3.7M annually with limited cash runway of ~1.4 years at current burn rate
  • ! Disproportionately high operating expenses with no credible path to profitability; would require 30x+ revenue growth to break even
  • ! Zero insider buying activity in 90 days suggests lack of confidence from management
  • ! Company operates as development-stage entity with minimal commercial traction relative to overhead

Key Metrics to Watch

Financial Metrics

Revenue
319.7K
Net Income
-10.3M
EPS (Diluted)
$-4.86
Free Cash Flow
-3.8M
Total Assets
6.5M
Cash
5.0M

Profitability Ratios

Gross Margin 68.4%
Operating Margin -3,269.4%
Net Margin -3,209.7%
ROE -272.8%
ROA -157.9%
FCF Margin -1,186.0%

Balance Sheet & Liquidity

Current Ratio
1.99x
Quick Ratio
1.06x
Debt/Equity
0.80x
Debt/Assets
42.1%
Interest Coverage
N/A
Long-term Debt
3.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-11T04:09:21.083459 | Data as of: 2025-12-31 | Powered by Claude AI